Wilson Kayla R, Villadangos Jose A, Mintern Justine D
Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC, Australia.
Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia.
Immunol Cell Biol. 2021 Oct;99(9):962-971. doi: 10.1111/imcb.12484. Epub 2021 Jul 2.
Dendritic cells (DCs) are essential for initiating immune responses. Depending on the environment, the type of DC and the way in which they interact with T cells, these immune responses can be beneficial or detrimental. DCs can be exploited as cellular vectors for vaccines against infection and cancer. The development and maintenance of DCs is dependent on the FMS-like tyrosine kinase 3 (Flt3)/Flt3 ligand (Flt3L) signaling cascade. Flt3 is also one of the most commonly mutated genes in acute myeloid leukemia and as such represents an attractive drug target. In this review, Flt3 is discussed with a particular focus on DCs. We detail the lifecycle of Flt3, from transcription to degradation, and interrogate recent studies as to how this pathway can be manipulated for immunotherapy, vaccination and treatment of autoimmune disease.
树突状细胞（DCs）对于启动免疫反应至关重要。根据环境、DC的类型以及它们与T细胞相互作用的方式，这些免疫反应可能有益也可能有害。DCs可被用作针对感染和癌症的疫苗的细胞载体。DCs的发育和维持依赖于FMS样酪氨酸激酶3（Flt3）/Flt3配体（Flt3L）信号级联反应。Flt3也是急性髓系白血病中最常发生突变的基因之一，因此是一个有吸引力的药物靶点。在本综述中，将特别关注DCs来讨论Flt3。我们详细阐述了Flt3从转录到降解的生命周期，并审视了关于如何操纵该信号通路用于免疫治疗、疫苗接种和自身免疫性疾病治疗的最新研究。
